Federal grants to Marker Therapeutics Inc
Marker Therapeutics Inc in Houston, Texas received $7.9 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cancer Treatment Research, with $6.7 million. In fiscal 2025 it was awarded $3.5 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$7.9 million
- Awards5
- Awarded in FY 2025$3.5 million
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 1 | $519,750 |
| FY 2023 | 1 | $664,838 |
| FY 2024 | 5 | $3.2 million |
| FY 2025 | 5 | $3.5 million |
Programs that fund Marker Therapeutics Inc
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 4 | $6.7 million |
| Food and Drug Administration Research | 1 | $1.2 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $7.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Controlling tumor immune escape in pancreatic cancer using a dual t cell product strategy - abstract while t cell therapies have shown efficacy in hematologic malignancies, extension of this success to solid tumors has proven to be challenging, mainly due to the immunosuppressive and hostile tumor m | Cancer Treatment Research | June 14, 2024 | $2.0 million |
| Phase 2 clinical trial of a novel t cell therapy following bridging therapy with hypomethylating agents for relapsed aml patients post-stem cell transplant - abstract this phase II application will advance MT-401, a novel multi-tumor associated antigen (MTAA)-specific t cell product for the treatmen | Cancer Treatment Research | August 8, 2023 | $2.0 million |
| A phase 1 study of patient-derived multi-tumor associated antigen specific t cells (MT-601) administered to patients with metastatic pancreatic cancer following frontline folfirinox - abstract pancreatic cancer (PC) is an orphan disease with a 5-YEAR relative survival of 11.5% and relative survival | Cancer Treatment Research | August 30, 2024 | $1.3 million |
| A phase 1 study of patient-derived multi-tumor-associated antigen specific t cells (MT-601) administered to patients with relapsed non-hodgkin lymphoma - abstract this application presents MT-601, a novel multi-tumor associated antigen (MTAA)-specific t cell product for the treatment of non-hodgkin’ | Cancer Treatment Research | August 8, 2024 | $1.3 million |
| Efficacy of a multi-tumor-associated antigen-specific t cell therapy in aml patients following allogeneic stem cell transplant with minimal residual disease - abstract acute myeloid leukemia (AML) is a malignant neoplasm of myeloid lineage cells arising in the bone marrow and outgrowing normal hemat | Food and Drug Administration Research | September 8, 2022 | $1.2 million |
Questions people ask
How much federal grant money does Marker Therapeutics Inc get?
$7.9 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Marker Therapeutics Inc the most?
The Department of Health and Human Services, with $7.9 million in 5 awards.
What is Marker Therapeutics Inc's largest federal grant?
$2.0 million under Cancer Treatment Research, with its first action in the period on June 14, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Marker Therapeutics Inc?
Its largest are Cancer Treatment Research and Food and Drug Administration Research.
Other grant recipients in Houston
- Baylor College of Medicine
- The Univeristy of Texas M.D. Anderson Cancer Center
- Metropolitan Transit Authority of Harris County
- University of Texas Health Science Center at Houston
- Harris County
- University of Houston System
- William Marsh Rice University
- City of Houston
Largest federal grant recipients in Texas · Federal grants in Texas